Stray Dog
EN中文
EN中文

Prices are Hyperliquid perpetual futures: contracts that track each stock and trade 24/7. They are not exchange prices and can differ from them, most of all while US markets are closed. Change is over 24 hours. For information only.

  • TSLA—
  • PLTR—
  • HIMS—
  • SPCX—
  • SOFI—
  • BTC—
…Loading prices
HIMS

Competitive picture worsens as Amazon's One Medical launches a GLP-1 weight-loss programme aimed at its core business

Sources (3)

Amazon's One Medical formally launched a GLP-1 weight-management programme on 1 Sep, covering physician assessment, ongoing care and medication management. It sits alongside the oral Wegovy pill and Zepbound KwikPen already offered through Amazon Pharmacy, from $299 a month cash-pay, with home delivery by Amazon or collection from a kiosk.

Read more

Competition has jumped from platforms of a similar size, such as Ro, Noom and LifeMD, to a giant that brings the strongest logistics, payments and Prime traffic in the US. That lands on the weak spot HIMS exposed in Q2: gross margin collapsing from 76% to 64% as low-margin branded GLP-1 volume grew. This is not a fundamental inflection point but a competitive negative. It pushes down the industry's price anchor and raises the bar for winning customers, which is negative for the bulls' central question of whether earnings quality can be delivered.

Key evidence

  • PharmExec and others reported on 1 Sep that Amazon One Medical has launched a GLP-1 weight-management programme.
  • It is paired with the FDA-approved oral Wegovy pill and the Zepbound KwikPen already available on Amazon Pharmacy.
  • Cash-pay price from $299 a month, with some options covered by insurance.
  • Fulfilment through Amazon home delivery and pharmacy pick-up kiosks.
  • HIMS's gross margin in Q2 (reported 10 Aug) fell from 76% to 64%, mainly because of volume in low-margin branded GLP-1 drugs.
  • HIMS has nearly 2.9 million subscribers and revenue up 38% YoY.
  • HIMS's differentiation strategy: AI Care, smart scales, Labs and a peptide plant in California.

Catalysts to watch

  • A jump in profit in Q4 is the next key proof point
  • The pace at which HIMS's own peptide plant reaches capacity
  • How quickly Amazon's GLP-1 programme gains users, and how far its pricing pressure spreads

Risks

  • Amazon is unlikely to take over HIMS's base of nearly 2.9 million subscribers in the short term.
  • But by pulling down the industry's price anchor and raising the bar for winning customers, it puts HIMS's acquisition costs and pricing power under pressure.
  • The branded GLP-1 leg, HIMS's thinnest-margin business, faces another round of price-war pressure, which makes delivering on earnings quality harder.
  • The bulls' central question, whether HIMS is a product company or a fulfilment channel, has been forced into the open earlier than expected.
  • The core tension is unchanged: revenue up 38% year on year against erosion from both gross margin and compliance costs. Risk/reward is cautious.

Sources 3

  1. PharmExec
  2. Amazon One Medical (official)
  3. Amazon Pharmacy

A brief is a lead for our research, not a verified conclusion or advice.